Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
المؤلفون المشاركون
Sawaki, Akira
Nishida, Toshirou
Komatsu, Yoshito
Kanda, Tatsuo
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-01-22
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST).
Methods.
Twenty-six patients who had previously been exposed to both imatinib and sunitinib were enrolled in this study.
The treatment regimen was BSC with or without imatinib, based on the patient’s choice after discussion with his or her physician.
The primary endpoint was overall survival, and secondary endpoints were time to treatment failure, clinical response rate assessed by Choi criteria, and safety.
Results.
Fourteen patients were treated with imatinib plus BSC and 12 received BSC alone.
Median overall survival was greatly improved for the imatinib group, although differences were not significant (22 months for imatinib plus BSC versus 4 months for BSC; P=0.058).
Three patients (21%) had a clinical response in the imatinib group, and one had a clinical response in the BSC alone group.
Imatinib was well tolerated.
Conclusions.
Rechallenge with imatinib may be associated with improvement in overall survival without deteriorating performance status in patients who failed imatinib and sunitinib.
A prospective study should be considered to confirm the efficacy of rechallenge with imatinib.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sawaki, Akira& Kanda, Tatsuo& Komatsu, Yoshito& Nishida, Toshirou. 2014. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-464378
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sawaki, Akira…[et al.]. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-464378
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sawaki, Akira& Kanda, Tatsuo& Komatsu, Yoshito& Nishida, Toshirou. Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib. Gastroenterology Research and Practice. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-464378
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-464378
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر